Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05184283 · ClinicalTrials.gov registry record
Utilization of MAsS in Patients Undergoing LT for HCC
A clinical trial, sponsored by Columbia University.
- Terminated
- Registry status
- 11
- Enrollment target
NCT05184283: Clinical Trial study, sponsored by Columbia University.
NCT05184283 is a clinical trial that was terminated before completion, run by Columbia University. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05184283 was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- 11 participants
- Enrollment target
Study Summary
The aim of this study is to determine the effects of liver transplantation and standard immunosuppression on body composition in patients with compensated cirrhosis and hepatocellular carcinoma.
Primary Outcome
Muscle volume will be collected using body composition MR image acquisition that adds about 6-8 minutes acquisition time to the clinically prescribed MRI examination.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2022-06-16 |
| Est. Completion | 2023-11-29 |
Why NCT05184283 stopped before completion
NCT05184283 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 11 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT05184283 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05184283 about?
NCT05184283 is a clinical study titled "Utilization of MAsS in Patients Undergoing LT for HCC". The aim of this study is to determine the effects of liver transplantation and standard immunosuppression on body composition in patients with compensated cirrhosis and hepatocellular carcinoma.
What is the current status of trial NCT05184283?
This trial is currently terminated. The enrollment target is 11 participants. The study started on 2022-06-16. Estimated completion is 2023-11-29.
Who is sponsoring clinical trial NCT05184283?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI